Development of apricitabine halted without finding backer for Phase 3
On 10 May 2010, the Australian biotechnology company Avexa, announced the closure of the development programme for the nucleoside apricitabine (AVX754).
According to an earlier statement in March, initial three-week results from the study suggest activity against HIV with M184V mutation, associated with high-level resistance to 3TC and FTC.
Apricitabine is a cytidine analogue similar to 3TC and 48-week results from Phase 2b studies were presented at the HIV Congress in Glasgoew in 2008. 
Avexa were developing apricitabine under license from Shire Pharmaceuticals.
1. Avexa Press Statement (10 May 2010).
2. Cahn P et al. 48-week data from Study AVX-201 A randomised phase IIb study of apricitabine in treatment-experienced patients with M184V and NRTI resistance. 9th International Congress on Drug Therapy in HIV Infection Glasgow, 913 November 2008. Abstract O414.